Review November 2011: €5 million funding to fight blindness

Genable Technologies closed a €5 million funding round led by new investor Fountain Healthcare Partners and existing investor Delta Partners. The Dublin firm said it would use the funding to develop

1st January, 2012
Review November 2011: €5 million funding to fight blindness
Diarmuid Flavin, chief executive, Biosensia.

**Genable Technologies** closed a €5 million funding round led by new investor Fountain Healthcare Partners and existing investor Delta Partners. The Dublin firm said it would use the funding to develop new gene suppression and replacement therapies, including a new treatment for the genetic visual condition retinitis pigmentosa (RP).

Patients with RP have a mutation in the rhodopsin gene, which affects their eyesight, eventually leading to blindness.

**Biosensia**, a point-of-care diagnostics company based in Dublin,...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago